Schelman William 4

What Happened
William Schelman, Chief Medical Officer of Bicara Therapeutics (BCAX), was granted a derivative award covering 85,000 shares on May 8, 2026. The Form 4 lists the acquisition price as $0.00 (a zero-dollar grant/award), so there was no cash outlay by the insider. This is a compensation award (not a market purchase or sale).

Key Details

• Transaction date: May 8, 2026; Form 4 filed May 12, 2026 (filed within the usual two-business-day window).
• Transaction type/code: A — Grant/Award (derivative).
• Shares/units granted: 85,000 (price reported $0.00).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The award vests in sixteen equal quarterly installments beginning May 8, 2026, subject to continued service (per filing footnote F1).
• No indication of an immediate sale or exercise; this is an ongoing vesting award.

Context
Derivative grants like this are a common form of executive compensation to align incentives; they do not necessarily indicate immediate bullish or bearish trades because the shares vest over time and typically depend on continued employment or performance conditions. Retail investors should view this as standard compensation unless accompanied by immediate purchases or sales.